Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

136
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
136
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

115
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
115
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

196
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
196
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

115
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
115
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Peer review of the pesticide risk assessment of the active substance flurochloridone.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment of the active substance <i>Bacillus paralicheniformis</i> strain FMCH001.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment of the active substance <i>Bacillus subtilis</i> strain FMCH002.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment of the active substance cymoxanil.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment for the active substance bifenazate in light of confirmatory data submitted.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment of the active substance proquinazid.

EFSA journal. European Food Safety Authority·2026

相关实验视频

Updated: Dec 17, 2025

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
05:45

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality

Published on: April 7, 2023

3.4K

关于为EFSA进行通用的科学评估制定协议的指导.

, Simon More, Vasileios Bampidis

    EFSA journal. European Food Safety Authority
    |November 1, 2023
    PubMed
    概括

    本指南介绍了APRIO范式,用于制定科学评估问题,增强EFSA的功能.

    关键词:
    阿普里奥的时间.佩科 (PECO) 是一个国家.这就是PICOICO.一般的科学评估.这是指导,指导,指导.方法 方法 方法 方法.计划 计划 计划 计划 计划 计划问题制定问题表述.发展协议 发展协议

    更多相关视频

    Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
    16:02

    Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

    Published on: February 10, 2023

    2.7K
    Development and Testing of Species-specific Quantitative PCR Assays for Environmental DNA Applications
    08:54

    Development and Testing of Species-specific Quantitative PCR Assays for Environmental DNA Applications

    Published on: November 5, 2020

    13.1K

    相关实验视频

    Last Updated: Dec 17, 2025

    Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
    05:45

    Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality

    Published on: April 7, 2023

    3.4K
    Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
    16:02

    Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

    Published on: February 10, 2023

    2.7K
    Development and Testing of Species-specific Quantitative PCR Assays for Environmental DNA Applications
    08:54

    Development and Testing of Species-specific Quantitative PCR Assays for Environmental DNA Applications

    Published on: November 5, 2020

    13.1K

    科学领域:

    • 食品安全科学 食品安全科学
    • 风险评估方法 风险评估方法

    背景情况:

    • 欧洲食品安全局的2027年战略强调了对科学评估的强有力的协议的必要性.
    • 现有的协议开发框架需要协调和灵活性.

    研究的目的:

    • 为制定EFSA通用科学评估协议提供协调和灵活的框架.
    • 取代2020年协议开发框架草案.

    主要方法:

    • 介绍了APRIO (代理,路径,受体,干预,输出) 的问题制定模式.
    • 概述了确定证据需求和回答评估问题的方法的五种方法.
    • 包括关于不确定性分析的指导和协议模板.

    主要成果:

    • APRIO范式提供了一种结构化的方法,将参考条款转化为可回答的问题.
    • APRIO可以在EFSA的各个领域进行调整,旨在协调产出并促进一致性.
    • 该指南详细介绍了收集和分析证据的方法,包括专家判断和建模.

    结论:

    • 拟议的框架和APRIO范式增强了科学建议的适合目的协议的开发.
    • 本指南促进了EFSA科学评估过程中的一致性和适应性.
    • 推APRIO范式是因为它有潜力克服PICO/PECO等现有框架的挑战.